BioSpace News Archive

Mineralys Therapeutics, Inc. presented data from the Target-HTN Phase 2 trial that further defines an endotype-specific targeted approach for treating uncontrolled or resistant hypertension with lorundrostat, a highly selective aldosterone synthase inhibitor.

Milestone Pharmaceuticals Inc. announced positive Phase 2 data that show etripamil nasal spray resulted in rapid and statistically superior ventricular rate reduction and improved symptom-relief in patients with atrial fibrillation with rapid ventricular rate compared to placebo.

Longeveron Inc. announced that extended long-term follow-up data from the Company’s ELPIS I trial of Lomecel-BTM for patients with hypoplastic left heart syndrome is being presented as a poster at the annual Scientific Sessions of the American Heart Association, being held in Philadelphia, PA on November 11-13, 2023.

Kyverna Therapeutics, Inc., a patient-centered clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases, congratulates Peter A. Merkel, M.D., M.P.H., a member of the Kyverna’s scientific advisory board, on receiving the 2023 ACR Distinguished Clinical Investigator Award by the American College of Rheumatology.

Chroma Medicine, Inc. presented new preclinical data demonstrating that a single administration of its epigenetic editor efficiently and durably lowered PCSK9 and cholesterol levels in non-human primates in a late-breaking oral presentation at the 2023 American Heart Association Scientific Sessions, held November 11-13 in Philadelphia.

Ionis Pharmaceuticals, Inc. announced the completion of enrollment and positive preliminary findings from Part 1 of the ongoing HALOS Phase 1/2a study of ION582 in Angelman syndrome.

Alnylam Pharmaceuticals, Inc. announced positive results from the KARDIA-1 Phase 2 study of zilebesiran, an investigational RNAi therapeutic targeting liver-expressed angiotensinogen in development for the treatment of patients with hypertension and high cardiovascular risk.

UCB, a global biopharmaceutical company, will present a post hoc analysis of the EXXELERATE trial examining the efficacy of CIMZIA® and adalimumab in patients with rheumatoid arthritis with high rheumatoid factor levels.

Kyverna Therapeutics, Inc. announced the presentation at the 96th Congress of the German Society of Neurology in Berlin, Germany, of a late breaking abstract describing the case of a 33 year-old myasthenia gravis patient that underwent treatment with KYV-101 on a named patient basis outside of a clinical trial setting after having exhausted other treatment options.

Cleerly, the company working to create a new standard of care for the diagnosis of heart disease, announced the TRANSFORM trial at the American Heart Association’s 2023 Scientific Sessions.